Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

Authors

Yoshikazu Inoue (ORCID: https://orcid.org/0000-0003-3994-874X)
Kenya Muraishi
Yasuhiro Kondoh (ORCID: https://orcid.org/0000-0001-7456-5459)
Sakae Homma (ORCID: https://orcid.org/0000-0002-6213-3584)
Arata Azuma (ORCID: https://orcid.org/0000-0003-0506-9966)
Rie Ikeda (ORCID: https://orcid.org/0000-0003-2163-1031)
Takashi Ogura
Kaori Ochiai
Yukihiko Sugiyama
Toshihiro Nukiwa (ORCID: https://orcid.org/0000-0001-8712-1195)

Institutions

Toho University (JP)
Tohoku University (JP)
Boehringer Ingelheim (Japan) (JP)
Kanagawa Cardiovascular and Respiratory Center (JP)
Fukujuji Hospital (JP)
Nobuhara Hospital (JP)
Tosei General Hospital (JP)
NHO Kinki Chuo Chest Medical Center (JP)
Nippon Medical School (JP)

Publication Details

Journal: Advances in Therapy
Published: 2024-12-23
DOI: https://doi.org/10.1007/s12325-024-03079-2
Citations: 6
Primary Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type: article
Field-Weighted Citation Impact: 2.51

Funders

Boehringer Ingelheim Japan

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

Yoshikazu Inoue, Kenya Muraishi, Yasuhiro Kondoh, Sakae Homma et al.

Dec 23, 2024

6 citations

Advances in Therapy

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

2.51

article

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

Yoshikazu Inoue, Kenya Muraishi, Yasuhiro Kondoh, Sakae Homma, Arata Azuma, Rie Ikeda, Takashi Ogura, Kaori Ochiai, Yukihiko Sugiyama, Toshihiro Nukiwa

December 23, 2024article en

6 citations

Abstract

No abstract available for this paper.

Advances in TherapyVol. 42(2)

Toho University (JP), Tohoku University (JP), Boehringer Ingelheim (Japan) (JP), Kanagawa Cardiovascular and Respiratory Center (JP), Fukujuji Hospital (JP), Nobuhara Hospital (JP), Tosei General Hospital (JP), NHO Kinki Chuo Chest Medical Center (JP), Nippon Medical School (JP)

Boehringer Ingelheim Japan

Good health and well-being

Openalex Percentile: Top 10%

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

2.51

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan — Yoshikazu Inoue, Kenya Muraishi, et al. · Advances in Therapy (2024) | TGRS Research Map | TGRS